When a specialized player in diagnostic healthcare decides to tap public markets, investors naturally lean in to look at the numbers behind the lab coats. Q-Line Biotech Ltd is moving forward with its maiden public issue via the book-building route, aiming to mobilize Rs 214.48 crore at the upper price band. Operating in a niche segment spanning reagents, consumables, and diagnostic equipment, the company has spent over a decade building its market footprint across medical colleges, hospitals, and diagnostic service providers.
Inside the Business and Core Segments
Founded in 2013, the company develops, manufactures, and markets a diverse portfolio of in-vitro diagnostics (IVD) products. Its primary operational verticals cover clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and point-of-care devices. During the Covid-19 pandemic, the firm adapted quickly by developing testing kits like RT-PCR, RNA extraction, and viral transport media kits through its R&D unit and third-party technical collaborations.
Research and development play an integral part in the firm’s day-to-day operations. As of March 31, 2026, the company employed 19 personnel in its R&D labs, making up about 5.25% of its total permanent workforce of 362 employees. In addition to permanent staff, the company engaged 223 contract workers across various departments.
Structure and Timelines of the Public Issue
The IPO consists entirely of a fresh issue of 6,253,200 equity shares with a face value of Rs 10 each. The price band is fixed between Rs 326 and Rs 343 per share. Investors must apply for a minimum lot size of 800 shares, and in multiples of 400 shares thereafter. At the upper end of the price band, the cost of one lot comes to Rs 2,74,400 based on simple multiplication of the lot size and price.
The bidding window opens on May 21, 2026, and closes on May 25, 2026. The total issue size accounts for 26.81% of the post-issue paid-up equity capital. Equity shares will list on the NSE SME Emerge platform. Prior to this public push, the firm raised Rs 27.44 crore through a pre-IPO placement of 800,000 shares at Rs 343 each in May 2026.
Where the Money Goes
Understanding how a company plans to deploy capital tells you a lot about its immediate pressures. Out of the net proceeds from the IPO, Rs 93.50 crore is earmarked for working capital requirements, while Rs 90.00 crore will go toward the repayment or prepayment of specific borrowings. The remaining funds are designated for general corporate purposes. This heavy allocation toward debt reduction highlights the capital-intensive nature of scaling a diagnostic manufacturing operation.
Hem Securities Ltd and Share India Capital Services Pvt Ltd are the joint lead managers for the issue, while Purva Sharegistry (India) Pvt. Ltd acts as the registrar. Hem Finlease Pvt. Ltd serves as the market maker and syndicate member. Together, the lead managers have handled 79 issues over the past three years, with 8 of those closing below their issue price on their listing day.
Financial Track Record and Valuation Realities
The company’s financial performance displays notable top-line expansion alongside bottom-line turbulence. On a consolidated basis, total income and net profit stood at Rs 184.81 crore and Rs 32.10 crore for FY23, moving to Rs 206.45 crore and Rs 34.44 crore for FY24, and reaching Rs 322.58 crore and Rs 28.13 crore for FY25. For the nine-month period ended December 31, 2025, the firm posted a net profit of Rs 38.69 crore on a total income of Rs 236.50 crore.
While revenue scaled up impressively, profit dipped during FY25 due to an extraordinary item of Rs 16.97 crore. The sharp earnings jump in the pre-IPO nine-month stretch of FY26 raises natural questions regarding sustainability. Furthermore, contingent liabilities stood at Rs 61.64 crore and overall borrowings reached Rs 242.57 crore as of December 31, 2025.
The asking price translates to a price-to-earnings (P/E) ratio of 15.51 if we annualize or attribute the strong 9M FY26 earnings to the post-IPO fully diluted equity base, and a P/E of 28.44 based on FY25 earnings. The company reports an average EPS of Rs 25.00 and an average RoNW of 23.17% for the last two fiscals. The issue is priced at a price-to-book value of 2.44 relative to a net asset value of Rs 140.81 per share as of December 31, 2025.
Final Takeaway for Investors
Because the offer document notes no direct listed peers in the segment, the pricing attempts to capture a unique diagnostic premium. The valuation feels full when considering the fluctuating profit history and heavy debt load sitting on the balance sheet. Well-informed investors comfortable with SME market volatility may choose to park moderate funds with a long-term horizon.
Frequently Asked Questions
The company is looking to mobilize Rs 214.48 crore at the upper price band through the issuance of 6,253,200 equity shares.
The price band is set from Rs 326 to Rs 343 per equity share. The minimum application lot size is 800 shares.
The IPO opens for subscription on May 21, 2026, and closes on May 25, 2026.
The shares will be listed on the NSE SME Emerge platform.
The company intends to use Rs 93.50 crore for working capital requirements, Rs 90.00 crore for the repayment or prepayment of certain borrowings, and the remainder for general corporate purposes.
The IPO is jointly lead managed by Hem Securities Ltd and Share India Capital Services Pvt. Ltd.
For 9M FY26 ended December 31, 2025, the company posted a net profit of Rs 38.69 crore on a total income of Rs 236.50 crore.
